Related Experiment Video
Updated: Aug 9, 2026
Human In Vitro Suppression as Screening Tool for the Recognition of an Early State of Immune Imbalance
Published on: July 22, 2011
An in vitro study of how much methylprednisolone is needed to produce immunosuppression
Abstract:
An in vitro assay system (MLR-LMC) was used to study the optimal time-concentration characteristics of methylprednisolone as an immunosuppressive drug. Our data suggest that low doses of methylprednisolone (less than 40 mg) most probably contribute little to immunosuppressive therapy and that high doses (15 to 30 mg/kg) are most probably excessive. Clinical trials are necessary to establish the validity of these conclusions and to establish the optimal dose schedule for the administration of steroids to patients undergoing renal transplantation.
Insights
Optimal immunosuppressive therapy requires careful dosing of methylprednisolone. Low doses may be ineffective, while high doses might be excessive, necessitating clinical trials for renal transplant patients.
Area of Science:
- Immunopharmacology
- Transplantation Medicine
Background:
- Methylprednisolone is a key immunosuppressive drug used in organ transplantation.
- Determining optimal dosing is crucial for efficacy and minimizing toxicity.
Purpose of the Study:
- To investigate the optimal time-concentration dynamics of methylprednisolone.
- To identify potential dose ranges for effective immunosuppression in renal transplant recipients.
Main Methods:
- Utilized an in vitro mixed lymphocyte reaction-lymphocyte-mediated cytotoxicity (MLR-LMC) assay system.
- Evaluated methylprednisolone's effects across various concentrations and time points.
Main Results:
- Low methylprednisolone doses (< 40 mg) showed minimal immunosuppressive effects.
- High doses (15-30 mg/kg) appeared excessive, suggesting a narrow therapeutic window.
Conclusions:
- The study highlights the need for precise methylprednisolone dosing in immunosuppressive therapy.
- Further clinical trials are essential to validate these findings and establish optimal dosing schedules for renal transplant patients.
More Related Videos
18:48In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
Published on: August 12, 2017
09:09Generating a Reproducible Model of Mid-Gestational Maternal Immune Activation using Poly(I:C) to Study Susceptibility and Resilience in Offspring
Published on: August 17, 2022